Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00831)
Name
Amifampridine
Synonyms    Click to Show/Hide the Synonyms of This API
3,4-DIAMINOPYRIDINE; 54-96-6; pyridine-3,4-diamine; Amifampridine; 3,4-Pyridinediamine; 3,4-DAP; Firdapse; 4,5-Diaminopyridine; Diamino-3,4 pyridine; SC10; Zenas; Pyridine, 3,4-diamino-; UNII-RU4S6E2G0J; 3-amino-4-pyridinylamine; MFCD00006401; RU4S6E2G0J; 54-96-6 (free base); CHEMBL354077; 54-96-6 3,4-diaminopyridine; WT559; NSC-521760; NCGC00167560-01; DSSTox_CID_26715; DSSTox_RID_81847; DSSTox_GSID_46715; 3,4-Diaminopyridine, 98%; amifampridin; Ruzurgi; CAS-54-96-6; SMR000752913; 3,4 Diaminopyridine; EINECS 200-220-9; NSC 521760; BRN 0110232; Amifampridine [USAN:INN:BAN]; Ruzurgi (TN); Pyridine,4-diamino-; PubChem1295; 3,4-diamino pyridine; 3,4-diamino-pyridine; ACMC-209lkh; 3,4-Diammoniopyridinium; WLN: T6NJ CZ DZ; Amifampridine (USAN/INN); 4-DAP; SCHEMBL21273; 5-22-11-00266 (Beilstein Handbook Reference); MLS001304911; MLS001333181; MLS001333182; GTPL8032; 3,4-Diamino[3,4-b]pyridine; DTXSID6046715; AMPD00217; CHEBI:135948; HMS2233K06; ZINC164000; ACN-S003268; ACT01546; ALBB-005969; BCP22343; Amifampridin (3,4-Diaminopyridine); Tox21_112555; ANW-32223; BBL013269; BDBM50416493; CL0116; NSC521760; NSC790505; s4622; SBB004341; STK503647; AKOS000672436; Tox21_112555_1; ACN-026994; CCG-304141; CM14022; DB11640; LS00018; MCULE-5478459845; NSC-790505; PS-9273; QC-1804; NCGC00167560-02; AK-26114; BP-12781; HY-14946; L421; AB0014693; DB-011105; AM20070030; D1149; FT-0614203; ST50946583; D10228; M-3620; 76674-EP2305250A1; 76674-EP2308868A1; 006D401; AC-907/34116043; Q411707; J-610017; W-105592; F0001-1409; L89
Clinical Status
Approved
PubChem CID
5918
Formula
C5H7N3
Canonical SMILES
C1=CN=CC(=C1N)N
InChI
1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
InChIKey
OYTKINVCDFNREN-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5918"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 109.13 Topological Polar Surface Area 64.9
XlogP -0.5 Complexity 74.1
Heavy Atom Count 8 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Amifampridine 10 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Colloidal Silicon Dioxide; Dibasic Calcium Phosphate Dihydrate; Magnesium Stearate; Microcrystalline Cellulose; Sodium Starch Glycolate
                   Dosage Form Tablet
                   Company Jacobus Pharmaceutical
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [1]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Calcium Stearate; Colloidal Silicon Dioxide; Microcrystalline Cellulose
                   Dosage Form Tablet
                   Company Catalyst Pharmaceuticals
References
1 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.